Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:CTNM NASDAQ:NTLA NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.53-3.9%$34.86$23.23▼$42.29$1.18B0.63374,314 shs253,915 shsCTNMContineum Therapeutics$12.44+5.3%$7.31$3.35▼$20.30$348.79M1.19147,556 shs130,501 shsNTLAIntellia Therapeutics$11.33-0.8%$11.61$5.90▼$23.76$1.21B2.284.10 million shs2.45 million shsXERSXeris Biopharma$7.49-2.5%$6.43$2.69▼$8.03$1.21B0.132.50 million shs1.21 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+3.58%-0.43%+3.14%+33.86%+7.90%CTNMContineum Therapeutics+0.08%+7.46%+74.96%+166.59%-34.02%NTLAIntellia Therapeutics+1.15%-1.72%+5.16%+37.42%-43.58%XERSXeris Biopharma-1.66%-2.66%+5.21%+76.55%+168.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.53-3.9%$34.86$23.23▼$42.29$1.18B0.63374,314 shs253,915 shsCTNMContineum Therapeutics$12.44+5.3%$7.31$3.35▼$20.30$348.79M1.19147,556 shs130,501 shsNTLAIntellia Therapeutics$11.33-0.8%$11.61$5.90▼$23.76$1.21B2.284.10 million shs2.45 million shsXERSXeris Biopharma$7.49-2.5%$6.43$2.69▼$8.03$1.21B0.132.50 million shs1.21 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+3.58%-0.43%+3.14%+33.86%+7.90%CTNMContineum Therapeutics+0.08%+7.46%+74.96%+166.59%-34.02%NTLAIntellia Therapeutics+1.15%-1.72%+5.16%+37.42%-43.58%XERSXeris Biopharma-1.66%-2.66%+5.21%+76.55%+168.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.00Buy$42.3312.79% UpsideCTNMContineum Therapeutics 3.17Buy$22.7582.88% UpsideNTLAIntellia Therapeutics 2.56Moderate Buy$27.11139.39% UpsideXERSXeris Biopharma 2.83Moderate Buy$7.08-5.37% DownsideCurrent Analyst Ratings BreakdownLatest CTNM, XERS, COLL, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.008/18/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $21.008/13/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/12/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.008/11/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$44.008/11/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $60.008/8/2025NTLAIntellia TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$50.00 ➝ $45.008/8/2025NTLAIntellia TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $21.008/8/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.006/20/2025CTNMContineum TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform6/16/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$7.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.87$12.31 per share3.05$7.10 per share5.29CTNMContineum Therapeutics$50M6.98N/AN/A$7.66 per share1.62NTLAIntellia Therapeutics$57.88M21.00N/AN/A$8.56 per share1.32XERSXeris Biopharma$203.07M5.95N/AN/A($0.20) per share-37.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.0435.976.23N/A5.13%97.28%13.87%11/6/2025 (Estimated)CTNMContineum Therapeutics-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%11/5/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$4.69N/AN/AN/A-908.48%-57.48%-45.04%11/6/2025 (Estimated)XERSXeris Biopharma-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)Latest CTNM, XERS, COLL, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NTLAIntellia Therapeutics-$1.03-$0.99+$0.04-$0.98$12.26 million$14.25 million8/7/2025Q2 2025XERSXeris Biopharma-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 million8/5/2025Q2 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.271.181.10CTNMContineum TherapeuticsN/A24.5124.51NTLAIntellia TherapeuticsN/A5.195.19XERSXeris BiopharmaN/A1.951.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ACTNMContineum TherapeuticsN/ANTLAIntellia Therapeutics88.77%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%CTNMContineum Therapeutics11.30%NTLAIntellia Therapeutics3.10%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableCTNMContineum Therapeutics3128.04 million24.87 millionN/ANTLAIntellia Therapeutics600107.35 million104.02 millionOptionableXERSXeris Biopharma290161.48 million151.03 millionOptionableCTNM, XERS, COLL, and NTLA HeadlinesRecent News About These CompaniesXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 12 at 2:40 AM | marketbeat.comWhat Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?September 9 at 1:01 PM | zacks.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Significant Decline in Short InterestSeptember 9 at 2:57 AM | americanbankingnews.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest Down 26.7% in AugustSeptember 9 at 2:53 AM | marketbeat.comParkman Healthcare Partners LLC Has $9.78 Million Stock Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 8, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Downgraded by Wall Street Zen to BuySeptember 8, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 7, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Stock Holdings Raised by Graham Capital Management L.P.September 7, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Rating Lowered by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comBosun Asset Management LLC Acquires New Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 6, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High - Time to Buy?September 5, 2025 | marketbeat.comXeris In Recorlev-Fuelled Growth: Why I Choose To BuySeptember 5, 2025 | seekingalpha.comPDT Partners LLC Buys New Shares in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comIeq Capital LLC Boosts Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comQuarry LP Makes New $388,000 Investment in Xeris Biopharma Holdings, Inc. $XERSSeptember 3, 2025 | marketbeat.comAlpine Global Management LLC Has $549,000 Stock Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 2, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Shares Purchased by Driehaus Capital Management LLCSeptember 2, 2025 | marketbeat.comWellington Management Group LLP Has $2.15 Million Stake in Xeris Biopharma Holdings, Inc. $XERSSeptember 2, 2025 | marketbeat.comRussell Investments Group Ltd. Buys 113,713 Shares of Xeris Biopharma Holdings, Inc. $XERSSeptember 1, 2025 | marketbeat.comJeffrey Sherman Sells 42,232 Shares of Xeris Biopharma (NASDAQ:XERS) StockAugust 30, 2025 | insidertrades.comQuantbot Technologies LP Purchases Shares of 54,107 Xeris Biopharma Holdings, Inc. $XERSAugust 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTNM, XERS, COLL, and NTLA Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$37.53 -1.53 (-3.91%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Contineum Therapeutics NASDAQ:CTNM$12.44 +0.63 (+5.33%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Intellia Therapeutics NASDAQ:NTLA$11.32 -0.10 (-0.83%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Xeris Biopharma NASDAQ:XERS$7.48 -0.20 (-2.54%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
